1. Introduction {#sec1}
===============

With the rapid progress of RNA-sequencing technology, long noncoding RNA has greatly drawn more and more attention of society \[[@B1], [@B2]\]. LncRNAs were one class of non-protein-coding RNA molecules, which are greater than 200 nucleotides in length, without open reading frame \[[@B3]--[@B5]\]. To our knowledge, accumulating studies have detected a variety of aberrant expression lncRNAs in multiple human cancers. In spite the "junk" of genome lncRNAs being considered as insignificant, they are now confirmed to exert pivotal roles in tumor biological processes, including carcinogenic or antitumor effects via transcriptional and posttranscriptional regulations \[[@B6], [@B7]\]. Furthermore, emerging evidence has indicated that the abnormal expression of lncRNAs was correlated with progression of neoplasms, including clinical-pathological features and prognostic outcomes \[[@B7]--[@B12]\]. Therefore, lncRNA can serve as a potential biomarker for predicting progression and survival in patients with carcinomas. To better understand the tumor mechanism at lncRNA level, it is of primary necessity to predict potential disease-lncRNA association, which could also benefit the detection of novel biomarkers for cancer treatment and prognosis. However, in previous years, there have been very limited computational models to experimentally confirm the disease-lncRNA associations.

In recent years, lncRNA linc00152 has caught great attention due to its involvement in multiple cancers. In 2013 Cao et al. generated the lncRNA expression profiles in gastric cancer by using robust multiarray average method, and first reported the differentially expressed lncRNA linc00152 in tumor tissues \[[@B13]\]. It has been showed that linc00152 was overexpressed in multiple types of cancers, including gastric cancer, renal cell carcinoma, gallbladder cancer, lung adenocarcinoma, and hepatocellular carcinoma \[[@B14]--[@B16]\]. In addition, knocking down linc00152 expression could inhibit cell migration, invasion, and proliferation and induce cell cycle arrest in G0/G1 and cell apoptosis in vitro \[[@B17], [@B18]\]. Elevated linc00152 expression was also found to be significantly associated with unfavorable prognosis in cancer patients. For instance, Hu et al. demonstrated that linc00152 expression was upregulated in ESCC specimens and high linc00152 level predicted shorter survival time \[[@B19]\]. Cai et al. have confirmed that linc00152 was correlated with poorer overall survival, as well as advanced lymph node metastasis and vessel invasion in gallbladder cancer patients \[[@B20]\]. However, certain investigations have presented the adverse results. Qiu and Yan declared that high linc00152 expression was related to superior overall survival in patients with colorectal carcinoma by using GSE dataset \[[@B21]\]. The discrepancies between these studies highlight the importance of evaluating the prognostic significance of linc00152 in human malignant neoplasms. Therefore, we carried out this systematic review and meta-analysis to clarify the predictive value of linc00152 in cancer patients.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

The literature retrieval was carried out by two independent reviewers (Chenkui Miao and Kai Zhao) through electronic databases including PubMed, Embase, Web of Science, and the Cochrane Library up to March 2017. The combinations of key words were used as follows: ("long non-coding RNA linc00152" or "lncRNA linc00152" or "linc00152") and ("cancer" or "carcinoma" or "neoplasm" or "tumor" or "malignancy"). The following criteria were utilized to screen appropriate articles: (1) English publications, (2) studies focusing on multiple malignancies; (3) associations between linc00152 and clinical outcomes. In order to supplement our literature search, the reference lists of relevant articles were observed for additional eligible studies.

2.2. Quality Assessment {#sec2.2}
-----------------------

We used a critical review checklist to evaluate the quality of all included studies. Quality assessment should contain the following criteria: (1) the study country and population, (2) the study design, (3) the detection of linc00152, (4) the cut-off points of linc00152, (5) the samples and pathology information, and (6) the clinical outcomes and follow-up duration. Articles were excluded when they did not cover the points above. A flow diagram of the study selection process is presented in [Figure 1](#fig1){ref-type="fig"}.

2.3. Data Extraction {#sec2.3}
--------------------

Two investigators independently extracted relevant data from included studies to rule out any discrepancy. Extracted data elements included the following records: (1) the first authors and year of publication, (2) the study nationality, (3) main ethnicity and cancer types, (4) sample and pathology type, (5) the cut-off value and assay method, (6) following-up months, (7) the case number of linc00152 expression, and (8) HRs, 95% CI, and *p* value for prognostic outcomes \[[@B22]\]. Those indirectly reported HRs and 95% CIs were extracted from graphical survival plots using Engauge Digitizer version 4.1 \[[@B23], [@B24]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

With the aim of testing the heterogeneity of pooled HRs, Cochran\'s *Q*-test and Higgins *I*^2^ statistics (*I*^2^) were performed in the meta-analysis. A fixed-effects model (Mantel-Haenszel method) or random-effects model (DerSimonian-Laird method) was conducted in accordance with the heterogeneity of included studies. When *p* \< 0.05 or the percentage of I2 was greater than 75%, a random-effects model was used to analyze the combined HR. Otherwise, a fixed-effects model was applied to analyses. Furthermore, in order to reduce the sources of heterogeneity, we also exerted subgroup analysis depending on various elements. Egger et al.\'s test was utilized to detect the publication bias \[[@B25], [@B26]\]. Stata version 12.0 (Stata Corporation, College Station, TX, USA) was used to calculate all statistical analyses.

3. Results {#sec3}
==========

3.1. Characteristics of Enrolled Studies {#sec3.1}
----------------------------------------

A total of 229 studies were initially retrieved from online database including PubMed, Embase, Web of science, and the Cochrane Library. After a manual screening of titles and abstracts, 205 studies were excluded according to the following reasons: reviews or non-English articles, nonhuman investigations, no association between linc00152 expression and human neoplasms and no prognostic outcomes or clinical parameters. After further screening of the remaining 24 studies, 16 were excluded due to lack of survival data, being unrelated to specific prognosis, or being reduplicative datasets. Finally, eight available studies were deemed applicable to the meta-analysis. The inclusion and exclusion reasons of candidate studies are presented in detail in [Figure 1](#fig1){ref-type="fig"}.

Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"} summarize the main characteristics of the selected 8 studies published from 2015 to 2017. The patients number of eight studies ranged from 35 to 205, with a mean subject size of 94. Among the eight studies, six studies reported patients\' OS; one focused on DFS and PFS, respectively. Five studies estimated the relationship between linc00152 and LNM, as well as four focusing on VI. The malignant neoplasms investigated consisted of gallbladder cancer, lung adenocarcinoma, and clear cell renal cell carcinoma (ccRCC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), colon cancer, and gastric cancer. All included studies were conducted in China and focused on Asian population. Tissue specimens were used to determine linc00152 expression in all studies except one in plasma samples. All of these studies were retrospective in design. Quantitative real-time PCR (qRT-PCR) was widely applied to determine the linc00152 expression.

3.2. Association between Linc00152 Expression and OS {#sec3.2}
----------------------------------------------------

A total of six original studies were performed to analyze the OS, with a fixed-effects model on account of no obvious heterogeneity (*p* = 0.655, *I*^2^ = 0%). Our meta-analysis indicated that high expression of linc00152 was correlated with poorer OS in patients with multiple carcinomas (HR = 2.05, 95% CI: 1.59--2.64; [Figure 2(a)](#fig2){ref-type="fig"}). In stratified analysis, we found that analyses for data from articles reported obtained a significant result between linc00152 and patients survival (HR = 2.03, 95% CI: 1.56--2.64), while those extracted from survival plots failed to get a meaningful outcome (HR = 2.33, 95% CI: 0.88--5.66; [Figure 3(a)](#fig3){ref-type="fig"}). Stratification analyses for other subgroups were presented in detail in Figures [3(b)](#fig3){ref-type="fig"}--[3(e)](#fig3){ref-type="fig"}.

3.3. Association between Linc00152 Expression and DFS/PFS {#sec3.3}
---------------------------------------------------------

In total, there were 2 studies including 196 patients investigating the prognostic significance of linc00152 on cancer progression or recurrence, with a pooled HR of 3.52 (95% CI: 1.82--6.79; [Figure 2(b)](#fig2){ref-type="fig"}). This result demonstrated that linc00152 overexpression predicted higher risk of cancer progression. Given no heterogeneity among the two studies, a fixed-effects model was performed to the calculation (*p* = 0.958, *I*^2^ = 0%). Among them, one focused on the prognostic value of linc00152 expression on cancer relapse (HR = 3.56, 95% CI: 1.59--7.97), and another one explored the association between linc00152 and tumor progression (HR = 3.43, 95% CI: 1.10--10.69). Linc00152 might serve as a crucial indicator for cancer progression.

3.4. Association between Linc00152 Expression and Clinicopathological Parameters {#sec3.4}
--------------------------------------------------------------------------------

A total of five studies comprising 369 cancer patients reported the correlation of linc00152 with LNM in multiple neoplasms. Since no significant heterogeneity was observed among these studies (*p* = 0.090, *I*^2^ = 50.2%), a fixed-effect model was utilized. The combined OR with 95% CI suggested that tumor tissues with high linc00152 expression of cancer patients preferentially metastasize to the lymph nodes (OR = 2.49, 95% CI: 1.57--3.94; [Figure 2(c)](#fig2){ref-type="fig"}).

Furthermore, four studies with 355 patients declared the relationship between linc00152 expression levels and vessel invasion of cancer patients, with a fixed-effects model due to no obvious heterogeneity (*p* = 0.133, *I*^2^ = 46.4%). Our results failed to demonstrate any significant association between aberrant linc00152 level and vessel invasion tendency (OR = 1.02, 95% CI: 0.54--1.93; [Figure 2(d)](#fig2){ref-type="fig"}). Only one study conducted the DM analysis of cancer patients, indicating that high linc00152 level could not accurately predict the occurrence of DM (OR = 0.600, 95% CI: 0.213--1.689; data not shown). This might be attributed to the limitation of large-scale investigations.

3.5. Publication Bias {#sec3.5}
---------------------

Begg\'s test and Egger\'s test were used to evaluate the publication bias in this meta-analysis. As is determined in the pooled analyses, Begg\'s funnel plots with pseudo 95% CIs were symmetric (Figures [4(a)](#fig4){ref-type="fig"}--[4(d)](#fig4){ref-type="fig"}). *p* values calculated from Egger\'s test with higher detection effectiveness were 0.258 for OS, 0.889 for LNM, and 0.612 for VI, respectively, indicating no significant publication bias in the meta-analysis.

3.6. Sensitivity Analyses {#sec3.6}
-------------------------

Sensitivity analysis was conducted by Stata12.0 software to assess whether exclusion of any individual study affected the overall results. The analyzed result from a fixed model suggested that our results are comparatively credible and stable (Figures [5(a)](#fig5){ref-type="fig"}--[5(d)](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

At the present time, significant achievements have been made in detecting promising biomarkers for multiple human carcinomas. Nevertheless, the survival outcome is still worse and has brought a great challenge to the public society. Numerous investigations have disclosed the aberrant expression of lncRNAs in tumor tissues compared with normal specimens \[[@B27]\]. LncRNAs have been reported to be involved in various biological activities such as cell proliferation, cycle, invasion, and metastasis \[[@B28]--[@B30]\]. As a kind of noncoding RNA with more than 200 nucleotides in length, lncRNAs lack the capacity of protein-coding. Recently, numerous studies have proposed its promising value as biomarkers for early tumor screening and prognosis, as well as clinical therapy for various types of carcinomas \[[@B31]--[@B33]\].

Long noncoding linc00152, one of the lncRNAs members, has been shown to be abnormally expressed in diverse types of cancer, such as gastric cancer, renal cell carcinoma, and gallbladder cancer, lung adenocarcinoma, and hepatocellular carcinoma, suggesting that linc00152 may develop a key role in carcinogenesis \[[@B14], [@B15], [@B17], [@B18], [@B20]\]. Chen et al. detected the linc00152 expression in human lung carcinoma tissues and paired normal tissues by using qRT-PCR and found that linc00152 was upregulated in tumor tissues. Inhibition of linc00152 suppressed cell growth, invasion, and migration and induced cell apoptosis \[[@B18]\]. High expression of linc0152 also predicted advanced TNM stage, larger tumor size, and lymph node metastasis, as well as shorter survival period. Yue et al. found that linc00152 overexpression was associated with poor overall survival and high recurrence risk in colon cancer. Further mechanism investigation revealed that the promoting role of linc00152 mainly depended on miR-193a-3p/ERBB4/AKT signaling axis, which may provide a novel choice confronting the drug resistance \[[@B35]\]. Additionally, in a gallbladder cancer study, evaluated linc00152 expression was found to be positively associated with advanced lymph node metastasis and vessel invasion and negatively correlated with patient\'s outcomes \[[@B20], [@B36]\]. However, there were available studies presenting the contradictory summary. By analyzing GSE datasets, Qiu and Yan confirmed that aberrant linc00152 level was an independent factor for unfavorable overall survival \[[@B21]\]. The observation of these antitumor values of linc00152 in cancers might cause doubt on their usual oncogenic function.

In addition, the prognostic and clinicopathological significance of linc00152 might partly be ascribed to its biological activities and molecular mechanisms. Knocking down linc00152 suppressed cell invasion and affects prognosis via interacting with EZH2 and repressing IL24 expression in lung carcinoma \[[@B18]\]. Linc00152 was negatively regulated by miR-376c-3p, restricting cell viability, and stimulates cell apoptosis in colorectal cancer \[[@B38]\]. In addition, Zhao et al. verified linc00152\'s promoting role in cell cycle arrest, migration, invasion, and epithelial-mesenchymal transition in gastric cancer, through affecting several molecular markers such as N-cadherin, E-cadherin, Vimentin, Slug, and Snail \[[@B39]\]. Considering its complex mechanisms, we speculated that linc00152 might be involved in various biological activities in diverse tumor subtypes. In this meta-analysis, we first assessed the correlation of linc00152 with prognostic outcomes (OS, DFS, and PFS) and clinical parameters (LNM, VI). We also performed subgroup, sensitivity, and heterogeneity analyses to explore the effects of dominant characteristics from available studies. We found that upregulated linc00152 expression induced unfavorable overall survival with a combined HR of 2.05 (95% CI: 1.59--2.64). Stratified analysis of OS demonstrated that data from article reported obtained a significant conclusion when evaluating the role of linc00152 in cancer patients (HR = 2.03, 95% CI: 1.56--2.64). Nevertheless, results for data extracted from survival curves made no sense (HR = 2.33, 95% CI: 0.88--5.66). These discrepancies might be attributed to the inaccuracy of the data from survival plots. In addition, the pooled outcome in the DFS/PFS analysis suggested that increased linc00152 level predicted advanced cancer progression (HR = 3.52, 95% CI: 1.82--6.79). On account of only two studies evaluating the cancer progression with aberrant linc00152 expression in two different types of tumors, it is of no great worth to perform the stratified analyses. Also, what cannot be ignored is the difference of samples between included studies from different lab and institution. This might minimize the reliability of our results at some level. Although samples including in the meta-analysis were differential between studies, a significant association between linc00152 and patients\' OS and DFS/PFS could still be reached. However, more high quality and available investigations are needed for further evidence.

Admittedly, numerous studies have shown that linc00152 could promote tumor metastasis and invasion in cancer patients. In the meta-analysis, we demonstrated that high expression of linc00152 was positively correlated with advanced LNM (OR = 2.49, 95% CI: 1.57--3.94); nevertheless abnormal miR-152 expression exerted no statistical significance in VI (OR = 1.02, 95% CI: 0.54--1.93). The deficiencies of studies focusing on linc00152 and clinical characteristics might account for this discrepancy to some extent. Furthermore, the differences between malignancies types also had considerable impacts on its prognostic and clinical role. In this meta-analysis, no significant heterogeneity was observed when we carried out OS and DFS/PFS analysis of linc00152, as well as comparison for LNM and VI. Furthermore, sensitivity analysis was also conducted to enhance the conclusion of this meta-analysis. Exclusion of any individual studies alters little change of the pooled significance. No obvious publication bias was detected in this meta-analysis, indicating our analysis was credible.

Despite the meta-analysis being performed with rigorous statistics, our conclusion still has several limitations for the following reasons. First, all investigations included were published in English, inducing English language bias in combined results \[[@B40], [@B41]\]. Second, the quantity of included studies was not sufficient for a more comprehensive result. Third, only Asian population were applicable in this meta-analysis, which might minimize the analyzing value to some level. Moreover, difference in samples from different institutions might reduce the credibility of our conclusion, which serves as an unavoidable factor in the study. Regarding these deficiencies, the role of linc00152 in multiple human malignancies might be exceedingly evaluated. Therefore, further large-scale and well-designed studies are needed to verify the function of linc00152 in various carcinomas.

To summarize, this meta-analysis reveals that long noncoding RNA linc00152 can predict poor prognostic and metastasis in multiple neoplasms, especially promoting advanced LNM. Considering the insufficient evidence, on purpose to better evaluate the prognostic role of linc00152 expression in malignant patients, more higher quality researches are required for further confirmation.
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![Flow diagram of the study selection process.](BMRI2017-6010721.001){#fig1}

![Forest plots of combined analyses associated with linc00152 expression. (a) Overall survival (OS); (b) disease-free survival/progression-free survival (DFS/PFS); (c) lymph node metastasis (LNM); (d) vessel invasion (VI).](BMRI2017-6010721.002){#fig2}

![Forest plots of stratified analysis of the OS (a) stratified by data source subgroup; (b) stratified by cut-off subgroup; (c) stratified by pathological subgroup; (d) stratified by sample subgroup; (e) stratified by tumor subgroup.](BMRI2017-6010721.003){#fig3}

![Begg\'s funnel plots of publication bias test. (a) Overall survival (OS); (b) disease-free survival/progression-free survival (DFS/PFS); (c) lymph node metastasis (LNM); (d) vessel invasion (VI).](BMRI2017-6010721.004){#fig4}

![Sensitivity analysis under specific model. (a) Effect of individual studies on the combined HR for OS; (b) effect of individual studies on the combined HR for DFS/PFS; (c) effect of individual studies on the pooled HR for LNM; (d) effect of individual studies on the pooled HR for VI.](BMRI2017-6010721.005){#fig5}

###### 

Main characteristics of included studies in the meta-analysis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study         Year   Tumor type            Case nationality   Median or mean age   Dominant ethnicity   Study design   Main pathological type   Tumor stage\           Detected sample   Outcome measures   Source of HR   Maximum months of follow-up
                                                                                                                                                  (I/II/III/IV)                                                              
  ------------- ------ --------------------- ------------------ -------------------- -------------------- -------------- ------------------------ ---------------------- ----------------- ------------------ -------------- -----------------------------
  Chen et al.   2017   Lung adenocarcinoma   China              65                   Asian                R              AdenoCA                  24/36 (I-II/IIIa)      Tissue            OS/PFS             SC             40

  Wu et al.     2016   ccRCC                 China              60                   Asian                R              AdenoCA                  22/55 (I/II--IV)       Tissue            OS                 Reported       80

  Hu et al.     2016   ESCC                  China              54.29                Asian                R              SqCa                     133/72 (I-II/III-IV)   Plasma            OS                 Reported       60

  Cai et al.    2016   Gallbladder cancer    China              60                   Asian                R              AdenoCA                  17/23 (I-II/III-IV)    Tissue            NR                 NR             NR

  Cai et al.    2016   Gallbladder cancer    China              60                   Asian                R              AdenoCA                  13/22 (I-II/III-IV)    Tissue            OS                 SC             40

  Yue et al.    2016   Colon cancer          China              65                   Asian                R              AdenoCA                  66/68 (II/III)         Tissue            OS/DFS             Reported       100

  Chen et al.   2016   Gastric cancer        China              60                   Asian                R              AdenoCA                  32/16 (I-II/III-IV)    Tissue            OS                 Reported       60

  Ji et al.     2015   HCC                   China              60                   Asian                R              AdenoCA                  61/41 (I-II/III-IV)    Tissue            NR                 NR             NR
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Study design is described as retrospective (R). AdenoCA, adenocarcinoma; SqCa, squamous carcinoma; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival. ccRCC, clear cell renal cell carcinoma; ESCC, esophageal squamous cell carcinoma; HCC, hepatocellular carcinoma. NR, not reported; SC, survival curve.

###### 

HRs and 95% CIs of cancer prognosis and progression associated with linc00152 expression in included studies.

  Study         Year   Tumor type            Main assay method   Cut-off value   Case number of linc00152 expression   OS   *P* value   DFS/PFS   *P* value                                                                                  
  ------------- ------ --------------------- ------------------- --------------- ------------------------------------- ---- ----------- --------- ----------- ---- ---- ---- -------------------------- -------- --------------------------- ---------
  Chen et al.   2017   Lung adenocarcinoma   qRT-PCR             Median          30                                    25   NR          NR        30          13   NR   NR   2.31 (0.66--8.04) U^*∗*^   0.005    3.43 (1.10--10.69) U^*∗*^   \<0.001
  Wu et al.     2016   ccRCC                 qRT-PCR             Mean            38                                    NR   8           4         39          NR   12   11   2.577 (1.233--5.387) M     0.012    NR                          NR
  Hu et al.     2016   ESCC                  qRT-PCR             NR              131                                   NR   NR          NR        74          NR   NR   NR   1.888 (1.220--2.581) M     0.0028   NR                          NR
  Cai et al.    2016   Gallbladder cancer    qRT-PCR             Median          23                                    15   NR          6         17          5    NR   3    NR                         NR       NR                          NR
  Cai et al.    2016   Gallbladder cancer    qRT-PCR             Median          18                                    12   NR          NR        17          5    NR   NR   2.14 (0.53--8.57) U^*∗*^   \<0.05   NR                          NR
  Yue et al.    2016   Colon cancer          qRT-PCR             Median          98                                    50   NR          7         38          18   NR   1    3.67 (1.64--8.21) M        0.002    3.56 (1.59--7.97) M         0.002
  Chen et al.   2016   Gastric cancer        qRT-PCR             Median          49                                    43   NR          NR        48          34   NR   NR   1.659 (1.008--2.731) M     0.047    NR                          NR
  Ji et al.     2015   HCC                   qRT-PCR             Median          51                                    NR   NR          9         51          NR   NR   6    NR                         NR       NR                          NR

The source of HR and 95% CI was extracted from survival curves or article reports. ^*∗*^HR calculated from survival curves; SC, survival curve; U, univariate analysis; M, multivariate analysis; NR, not reported. ccRCC, clear cell renal cell carcinoma; ESCC, esophageal squamous cell carcinoma; HCC, hepatocellular carcinoma. LNM, lymph node metastasis; DM, distant metastasis; VI, vessel invasion; OS, overall survival; DFS, disease-free survival; PFS, progression-free survival. qRT-qPCR, reverse transcriptase-quantitative PCR.
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